Literature DB >> 35450818

Mitochondrial micropeptide STMP1 promotes G1/S transition by enhancing mitochondrial complex IV activity.

Ye Sang1, Jin-Yu Liu1, Feng-Yi Wang1, Xiao-Yu Luo1, Zi-Qi Chen1, Shi-Mei Zhuang2, Ying Zhu3.   

Abstract

The roles of micropeptides in cell cycle regulation and cancer development remain largely unknown. Here we found that a micropeptide STMP1 (small transmembrane protein 1) was up-regulated in multiple malignancies including hepatocellular carcinoma (HCC), and its high level was associated with short recurrence-free survival of HCC patients. Gain- and loss-of-function analyses revealed that STMP1 accelerated cell proliferation and clonogenicity in vitro and tumor growth in vivo, and silencing STMP1 blocked G1/S transition. Mechanistically, STMP1 promoted the mRNA and protein levels of CCNE2, CDK2, and E2F1. STMP1 was localized in the inner membrane of mitochondria and interacted with mitochondrial complex IV and then enhanced its activity. Moreover, treatment with the mitochondrial complex IV inhibitor tetrathiomolybdate dramatically abrogated the promoting effect of STMP1 on cell proliferation and the expression of cyclin E2, CDK2, and E2F1. These results suggest that STMP1 may promote G1/S transition and cell proliferation by enhancing mitochondrial complex IV activity, which highlights STMP1 as a new regulator of the cell cycle and a potential target for anti-cancer therapy.
Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  G1/S transition; HCC; STMP1; micropeptide; mitochondria

Mesh:

Substances:

Year:  2022        PMID: 35450818      PMCID: PMC9372290          DOI: 10.1016/j.ymthe.2022.04.012

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  34 in total

Review 1.  Cell cycle proliferation decisions: the impact of single cell analyses.

Authors:  Jacob P Matson; Jeanette G Cook
Journal:  FEBS J       Date:  2016-10-05       Impact factor: 5.542

2.  Mitochondrial Genomic Backgrounds Affect Nuclear DNA Methylation and Gene Expression.

Authors:  Carolyn J Vivian; Amanda E Brinker; Stefan Graw; Devin C Koestler; Christophe Legendre; Gerald C Gooden; Bodour Salhia; Danny R Welch
Journal:  Cancer Res       Date:  2017-06-29       Impact factor: 12.701

3.  Functional prediction and physiological characterization of a novel short trans-membrane protein 1 as a subunit of mitochondrial respiratory complexes.

Authors:  Dapeng Zhang; Yanwei Xi; Maria L Coccimiglio; Jan A Mennigen; Michael G Jonz; Marc Ekker; Vance L Trudeau
Journal:  Physiol Genomics       Date:  2012-10-16       Impact factor: 3.107

Review 4.  Mining for Micropeptides.

Authors:  Catherine A Makarewich; Eric N Olson
Journal:  Trends Cell Biol       Date:  2017-05-18       Impact factor: 20.808

5.  The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

Authors:  Changhan Lee; Jennifer Zeng; Brian G Drew; Tamer Sallam; Alejandro Martin-Montalvo; Junxiang Wan; Su-Jeong Kim; Hemal Mehta; Andrea L Hevener; Rafael de Cabo; Pinchas Cohen
Journal:  Cell Metab       Date:  2015-03-03       Impact factor: 27.287

6.  KLF6 Suppresses Metastasis of Clear Cell Renal Cell Carcinoma via Transcriptional Repression of E2F1.

Authors:  Yu Gao; Hongzhao Li; Xin Ma; Yang Fan; Dong Ni; Yu Zhang; Qingbo Huang; Kan Liu; Xintao Li; Lei Wang; Liangyou Gu; Yuanxin Yao; Qing Ai; Qingshan Du; Erlin Song; Xu Zhang
Journal:  Cancer Res       Date:  2016-10-25       Impact factor: 12.701

Review 7.  Targeting mitochondria metabolism for cancer therapy.

Authors:  Samuel E Weinberg; Navdeep S Chandel
Journal:  Nat Chem Biol       Date:  2015-01       Impact factor: 15.040

Review 8.  Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.

Authors:  Leoni A Kunz-Schughart; Geoff S Higgins; Thomas M Ashton; W Gillies McKenna
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

9.  E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition.

Authors:  Kamila Burdova; Hongbin Yang; Roberta Faedda; Samuel Hume; Jagat Chauhan; Daniel Ebner; Benedikt M Kessler; Iolanda Vendrell; David H Drewry; Carrow I Wells; Stephanie B Hatch; Grigory L Dianov; Francesca M Buffa; Vincenzo D'Angiolella
Journal:  EMBO J       Date:  2019-08-19       Impact factor: 11.598

10.  LncRNA Lnc-APUE is Repressed by HNF4α and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis.

Authors:  Song-Yang Li; Ying Zhu; Ruo-Nan Li; Jia-Hui Huang; Kai You; Yun-Fei Yuan; Shi-Mei Zhuang
Journal:  Adv Sci (Weinh)       Date:  2021-02-01       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.